Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 12-Month Low – Should You Sell?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s stock price reached a new 52-week low during trading on Friday . The company traded as low as $281.77 and last traded at $287.1620, with a volume of 170604 shares. The stock had previously closed at $289.39.

Analysts Set New Price Targets

ALNY has been the topic of a number of research reports. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Truist Financial reduced their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Jefferies Financial Group reiterated a “hold” rating and issued a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $463.13.

Alnylam Pharmaceuticals Price Performance

The firm’s 50-day moving average is $305.23 and its 200-day moving average is $344.11. The company has a market capitalization of $38.26 billion, a PE ratio of 78.28 and a beta of 0.29. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the business earned ($0.44) earnings per share. The firm’s quarterly revenue was up 96.4% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 7,740 shares of company stock valued at $2,420,214. Company insiders own 0.86% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. First Horizon Corp boosted its position in Alnylam Pharmaceuticals by 20.7% during the fourth quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 28 shares during the period. Yousif Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock valued at $666,000 after buying an additional 29 shares during the period. Bessemer Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 15.6% during the third quarter. Bessemer Group Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 30 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares during the last quarter. Finally, Golden State Wealth Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 36 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.